Janux Therapeutics Inc (JANX) Stock Statistics & Valuation Metrics

Janux Therapeutics Inc has a market cap or net worth of $1.09B. The enterprise value is $16.79M.

Market Cap

$1.09B

Enterprise Value

$16.79M

Janux Therapeutics Inc has 61,136,772 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

61,136,772

Owned by Insiders

19.89%

Owned by Institutions

30.66%

Janux Therapeutics Inc’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -16.01%.

Return on Equity (ROE)

-0.12

Return on Assets (ROA)

-0.11

Return on Invested Capital (ROIC)

-16.01%

Return on Capital Employed (ROCE)

-0.16

Revenue Per Employee

88.50K

Profits Per Employee

-1.01M

Employee Count

113

Asset Turnover

0.01

Inventory Turnover

0.00

The current PE Ratio of Janux Therapeutics Inc is -11.02. Janux Therapeutics Inc’s PEG ratio is -1.73.

PE Ratio

-11.02

PS Ratio

46.31

PB Ratio

1.23

Price to FCF

-26.51

Price to Operating Cash Flow

-27.74

PEG Ratio

-1.73

In the last 12 months, Janux Therapeutics Inc had revenue of 10.00M and earned -113.63M in profits. Earnings per share was -1.83.

Revenue

10.00M

Gross Profit

7.97M

Operating Income

-157.67M

Pretax Income

-113.63M

Net Income

-113.63M

EBITDA

-111.60M

Earnings Per Share (EPS)

-1.83

In the last 12 months, operating cash flow was -41.25M and capital expenditures -674,000, giving a free cash flow of -41.92M billion.

Operating Cash Flow

-41.25M

Free Cash Flow

-41.92M

Free Cash Flow per Share

-0.67

Janux Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-3.78%

Earnings Yield

-8.98%

Beta

1.21

52-Week Price Change

-32.69%

50-Day Moving Average

17.63

200-Day Moving Average

15.39

Relative Strength Index (RSI)

55.14

Average Volume (3m)

834.67K

Janux Therapeutics Inc upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 06, 2026

Next Earnings Date

Nov 10, 2026

Ex-Dividend Date

―

Janux Therapeutics Inc as a current ratio of 39.04, with Debt / Equity ratio of 2.31%

Current Ratio

39.04

Quick Ratio

39.04

Debt to Market Cap

0.00

Net Debt to EBITDA

0.27

Interest Coverage Ratio

0.00

In the past 12 months, Janux Therapeutics Inc has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Janux Therapeutics Inc EV to EBITDA ratio is -10.96, with an EV/FCF ratio of -26.32.

EV to Sales

45.98

EV to EBITDA

-10.96

EV to Free Cash Flow

-26.32

EV to Operating Cash Flow

-26.75

Janux Therapeutics Inc has $970.91M in cash and marketable securities with $20.99M in debt, giving a net cash position of $949.92M billion.

Cash & Marketable Securities

$970.91M

Total Debt

$20.99M

Net Cash

$949.92M

Net Cash Per Share

$15.54

Tangible Book Value Per Share

$14.74

Gross margin is 100.00%, with operating margin of -598.15%, and net profit margin of -427.47%.

Gross Margin

100.00%

Operating Margin

-598.15%

Pretax Margin

-427.47%

Net Profit Margin

-427.47%

EBITDA Margin

-419.55%

EBIT Margin

-427.47%

The average price target for Janux Therapeutics Inc is $33.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$33.40

Price Target Upside

83.72% Upside

Analyst Consensus

Strong Buy

Analyst Count

11

Revenue Growth Forecast

5366.97%

EPS Growth Forecast

8.50%

Smart Score

6

AI Score

56